The **Call to Action Against Rare Cancers** was launched in June 2009 as part of the Rare Cancers Europe initiative. It is an international petition that urges policy-makers and all other relevant stakeholders to give high priority to quality treatment and care for patients with rare cancers.

**Please sign the Call to Action Against Rare Cancers to register your support:**

- **Your name:** ______________________________________________________
- **Your email address (optional):** ______________________________________
- **Your organisation (optional):** ______________________________________
- **Your signature:** __________________________________________________

**Please send to:**

**Rare Cancers Europe**
c/o European Society for Medical Oncology (ESMO)
Robert Schaefer
Brunnenstrasse 178/179
10119 Berlin, Germany, Fax: +49 (0)30 28 87 97 66

With the exception of your name and organisation, which will appear on the list of signatories on our Web site [www.rarecancerseurope.org](http://www.rarecancerseurope.org), your submitted details will not be published, shared or forwarded in any format.

**Rare Cancers Europe** is a joint initiative based on a partnership between the European Society for Medical Oncology (ESMO), the European Organisation for Rare Diseases (EURORDIS), the European Cancer Patient Coalition (ECPC), the European Organisation for Research and Treatment of Cancer (EORTC), Conticanet, EuroBoNeT, the World Sarcoma Network (WSN), the Association of European Cancer Leagues (ECL), the Chronic Myeloid Leukaemia Support Group, the International Brain Tumour Alliance (IBTA), Orphanet, the Chronic Myeloid Leukaemia Advocates Network, the Sarcoma Patients EuroNet Association (SPAEN), GIST Support UK & PAWS-GIST, Cancer 52, the International Kidney Cancer Coalition (IKCC), the Fondazione IRCCS Istituto Nazionale dei Tumori, the European Institute of Oncology (IEO), the European Society for Paediatric Oncology (SIOP Europe), the Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI), the European School of Oncology (ESO), the European Oncology Nursing Society (EONS), the European Society of Pathology (ESP), Novartis Oncology (initiating sponsor and industry partner), Pfizer Oncology (industry partner), and Sanofi (industry partner). The campaign is moreover supported by additional corporate supporters.

For more information about the initiative, please visit our website: [www.rarecancerseurope.org](http://www.rarecancerseurope.org) or contact us:

**Rare Cancers Europe**
c/o European Society for Medical Oncology (ESMO)
Tel: +49 (0) 30 28 87 97 55
Email: schaefer.robert@esmo.org